Journal Watch · Journal for ImmunoTherapy of Cancer · 2026

Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias.

Our approach and engineered multivalent anti-OX40 nanobody offer a powerful platform to advance immunotherapeutic strategies for cancer treatment.

Iemura T, Kitawaki T, Maeda R et al.Journal for ImmunoTherapy of Cancer3 min readPharma relevance 60/100

DOI: 10.1136/jitc-2025-014419PMID: 42547263Study type: preclinical (animal / model) study

TL;DR

Our approach and engineered multivalent anti-OX40 nanobody offer a powerful platform to advance immunotherapeutic strategies for cancer treatment.

Key findings

  • Trimerization of Nb479 facilitated potent OX40 activation without the need for a cross-linking scaffold.
  • Conjugation of the Nb479 trimer with an anti-serum albumin nanobody exhibited significantly improved pharmacokinetics in vivo and enhanced antitumor activity in a mouse model treated with CD19 chimeric antigen receptor T cells.<h4>Conclusion</h4>This study presents an innovative epitope-directed approach that greatly accelerates the discovery of functionally potent agonistic nanobodies by effectively circumventing enrichment-driven epitope bias.
  • Our approach and engineered multivalent anti-OX40 nanobody offer a powerful platform to advance immunotherapeutic strategies for cancer treatment.

What they did

Representative nanobody clones underwent in vitro validation, including epitope mapping, binding affinity measurements, and functional assessments. Furthermore, we engineered the selected nanobody to enhance its in vivo efficacy. We also performed structural analysis of the nanobody-OX40 complex.<h4>Results</h4>Our epitope-directed approach efficiently identified nanobody clones recognizing functionally relevant epitopes distinct from dominant immunogenic regions. Notably, clone Nb479 demonstrated robust agonistic activity, closely mimicking the natural ligand gp34 with extensive OX40-binding interactions.

Full abstract (original)

Background: <h4>Background</h4>Conventional antibody discovery approaches that do not account for enrichment-driven biases, such as epitope immunogenicity, PCR amplification bias, or protein expression efficiency, may result in under-representation of rare yet functionally relevant clones, necessitating labor-intensive in vitro screening to identify agonistic antibodies among a large number of dominant clones. Thus, efficient screening methods for agonistic antibodies are urgently needed. OX40 is a promising target for cancer immunotherapy due to its role in enhancing T-cell activation and survival. However, effective anti-OX40 agonistic antibodies have not yet been developed.<h4>Methods</h4>We developed a novel screening strategy that involves the selection of nanobody clone pools enriched by biopanning against gp34-engaged and non-engaged OX40-expressing cells, next-generation sequencing, and computational clustering and subtraction analysis to identify clones recognizing the ligand-receptor interface.

What they did: Representative nanobody clones underwent in vitro validation, including epitope mapping, binding affinity measurements, and functional assessments. Furthermore, we engineered the selected nanobody to enhance its in vivo efficacy. We also performed structural analysis of the nanobody-OX40 complex.<h4>Results</h4>Our epitope-directed approach efficiently identified nanobody clones recognizing functionally relevant epitopes distinct from dominant immunogenic regions. Notably, clone Nb479 demonstrated robust agonistic activity, closely mimicking the natural ligand gp34 with extensive OX40-binding interactions.

Results & conclusions: Trimerization of Nb479 facilitated potent OX40 activation without the need for a cross-linking scaffold. Conjugation of the Nb479 trimer with an anti-serum albumin nanobody exhibited significantly improved pharmacokinetics in vivo and enhanced antitumor activity in a mouse model treated with CD19 chimeric antigen receptor T cells.<h4>Conclusion</h4>This study presents an innovative epitope-directed approach that greatly accelerates the discovery of functionally potent agonistic nanobodies by effectively circumventing enrichment-driven epitope bias. Our approach and engineered multivalent anti-OX40 nanobody offer a powerful platform to advance immunotherapeutic strategies for cancer treatment.

Abstract © the authors / Journal for ImmunoTherapy of Cancer (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1136/jitc-2025-014419 · PubMed 42547263.

Why it matters for pharma & biotech

  • Directly relevant to teams in cell therapy (CAR-T / engineered cells), small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: cell therapy (CAR-T / engineered cells) · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal for ImmunoTherapy of Cancer study find?

Our approach and engineered multivalent anti-OX40 nanobody offer a powerful platform to advance immunotherapeutic strategies for cancer treatment.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal for ImmunoTherapy of Cancer in 2026. Representative nanobody clones underwent in vitro validation, including epitope mapping, binding affinity measurements, and functional assessments.

Where can I read the original paper?

The original is at the publisher via DOI 10.1136/jitc-2025-014419. PubMed ID: 42547263. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Iemura T, Kitawaki T, Maeda R et al.. Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias.. Journal for ImmunoTherapy of Cancer (2026). DOI: 10.1136/jitc-2025-014419.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/efficient-discovery-of-an-agonistic-anti-ox40-nanobody-by-epitope-direct-014419/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides